CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Umbralisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03364231
NCT03364231Phase 2Completed
CompareCT.gov

A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

TG Therapeutics, Inc.·interventional·Posted Dec 6, 2017·Updated Jun 23, 2023

In Brief

A Phase 2 clinical trial evaluating Umbralisib for Marginal Zone Lymphoma and 2 related conditions. Completed, enrolled 21 participants across 4 sites.

Detailed Summary

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 6, 2017
Enrollment StartNov 30, 2017
Primary CompletionFeb 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.6 years ago

Interventions

Umbralisibdrug

Oral Daily Dose